IFP Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

IFP Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.75K	Sell	796 -653	-45%	-$7.71K	﹤0.01%	3560
2026 Q2	$18.5K	Buy	1,449 +93	+7%	+$1.2K	﹤0.01%	3025
2026 Q1	$18.6K	Buy	1,356 +1,056	+352%	+$16.3K	﹤0.01%	2816
2025 Q4	$4.69K	Buy	300 +100	+50%	+$1.84K	﹤0.01%	3450
2025 Q3	$4.83K	Buy	+200	New	+$7.42K	﹤0.01%	3269
2025 Q2	–	Sell	-10,000	Closed	-$1.52K	–	5015
2025 Q1	$1.52K	Buy	+10,000	New	+$203K	﹤0.01%	3233
2024 Q1	–	Hold	0	–	-$1	–	3239
2023 Q4	–	Hold	0	–	–	–	3037
2023 Q3	–	Hold	0	–	–	–	3287
2023 Q2	–	Hold	0	–	–	–	3434
2023 Q1	–	Hold	0	–	–	–	3347
2022 Q4	–	Hold	0	–	–	–	4486
2022 Q3	–	Hold	0	–	–	–	4415
2022 Q2	–	Hold	0	–	–	–	4195
2022 Q1	–	Hold	0	–	–	–	4192
2021 Q4	–	Hold	0	–	–	–	3127
2021 Q3	–	Hold	0	–	–	–	3139
2021 Q2	–	Hold	0	–	–	–	3237
2021 Q1	–	Hold	0	–	–	–	2883
2020 Q4	–	Hold	0	–	–	–	3094
2020 Q3	–	Hold	0	–	–	–	1913

Other funds holding TNXP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Acorn Wealth Advisors Grand Blanc, Michigan $407M AUM 14.44% 1-Year Est. Return

Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Larson Financial Group St Louis, Missouri $4.11B AUM 23.62% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

IFP Advisors's TNXP Position: Q3 2026 in Review

IFP Advisors reduced its Tonix Pharmaceuticals (TNXP) stake by 45% in Q3 2026, selling an estimated $7.71K and leaving 796 shares worth $7.75K. The position accounts for ﹤0.01% of the portfolio, ranked #3560.

IFP Advisors first reported a position in TNXP in Q1 2025 and has held it in 6 quarters since. The position peaked at $18.6K in Q1 2026. 35 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

IFP Advisors held 796 shares of Tonix Pharmaceuticals worth $7.75K as of Q3 2026.
IFP Advisors sold 653 Tonix Pharmaceuticals shares in Q3 2026, an estimated $7.71K.
Tonix Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3560 holding.
IFP Advisors first reported a position in Tonix Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
IFP Advisors's Tonix Pharmaceuticals position peaked at $18.6K in Q1 2026.
35 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.